GLPwatch
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity
NCT06331286 · Unknown status
Last updated 2026-05-28This clinical trial is testing whether the medication dulaglutide, when used alongside standard treatments, can help improve thinking and memory in adults with bipolar disorder who also have obesity.
Status Unknown status The sponsor has not confirmed the status recently.
Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).
Type Interventional (clinical trial)
Design Randomized, open-label (no blinding) treatment study
Participants 60 people Planned (estimated).
Who can join Ages 18–65 · all sexes
Timeline Started 2023-09 · est. completion 2024-12
Where 1 site · China
What this study is testing ClinicalTrials.gov NCT06331286 ↗
Description as written by the study sponsor.
The primary objective of this study is to investigate the effect of dulaglutide adjuvant treatment in patients with bipolar disorder with obesity, in addition to exploring the effect of GLP-1RA on cognition of bipolar disorder.
Treatments tested
- dulaglutide injection also known as diet and exercise guidance treatment Drug
0.75mg Subcutaneous injection once a week for 24 weeks
| Main thing measured | weight |
|---|---|
| Sponsor | First Affiliated Hospital of Zhejiang University |
| Conditions studied | Bipolar Disorder, Obesity, Cognition |
| GLP-1 drugs | dulaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06331286 ↗